Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $106,100 | 6 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valneva Austria GmbH | $104,453 | 2 | $0 (2022) |
| SANOFI PASTEUR INC. | $1,250 | 1 | $0 (2024) |
| GlaxoSmithKline, LLC. | $397.53 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,250 | 1 | SANOFI PASTEUR INC. ($1,250) |
| 2022 | $104,453 | 2 | Valneva Austria GmbH ($104,453) |
| 2018 | $380.42 | 2 | GlaxoSmithKline, LLC. ($380.42) |
| 2017 | $17.11 | 1 | GlaxoSmithKline, LLC. ($17.11) |
All Payment Transactions
6 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/14/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $1,250.00 | Research |
| Study: Safety, Tolerability, and Immunogenicity Dose-ranging Study of the Investigational Yellow Fever Vacine (vYF) Candidate Vaccine in Adults | ||||||
| 09/22/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $20,000.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | ||||||
| 01/19/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $84,452.60 | Research |
| Study: A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | ||||||
| 10/31/2018 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $259.98 | Research |
| Study: DPIV-002 | ||||||
| 10/31/2018 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $120.44 | Research |
| Study: DPIV-002 | ||||||
| 08/11/2017 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $17.11 | Research |
| Study: A Phase IIa, open label, controlled, mono center study to evaluate the efficacy, immunogenicity and safety of GSK Biologicals candidate malaria vaccines RTS,S AS01E and RTS,S AS01B administered as various dose schedules according to a 0, 1, 7 month or | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | Valneva Austria GmbH | $104,453 | 2 |
| Safety, Tolerability, and Immunogenicity Dose-ranging Study of the Investigational Yellow Fever Vacine (vYF) Candidate Vaccine in Adults | SANOFI PASTEUR INC. | $1,250 | 1 |
| DPIV-002 | GlaxoSmithKline, LLC. | $380.42 | 2 |
| A Phase IIa, open label, controlled, mono center study to evaluate the efficacy, immunogenicity and safety of GSK Biologicals candidate malaria vaccines RTS,S AS01E and RTS,S AS01B administered as various dose schedules according to a 0, 1, 7 month or | GlaxoSmithKline, LLC. | $17.11 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 68 | 111 | $32,844 | $9,179 |
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 48 | $13,824 | $4,217 | 30.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 22 | 39 | $7,800 | $2,277 | 29.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $6,684 | $1,537 | 23.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $4,536 | $1,148 | 25.3% |
About Dr. Michael Koren, M.D
Dr. Michael Koren, M.D is a Infectious Disease healthcare provider based in Silver Spring, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2010. The National Provider Identifier (NPI) number assigned to this provider is 1881914802.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Koren, M.D has received a total of $106,100 in payments from pharmaceutical and medical device companies, with $1,250 received in 2024. These payments were reported across 6 transactions from 3 companies. The most common payment nature is "" ($106,100).
As a Medicare-enrolled provider, Koren has provided services to 68 Medicare beneficiaries, totaling 111 services with total Medicare billing of $9,179. Data is available for 1 year (2023–2023), covering 4 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location Silver Spring, MD
- Active Since 06/02/2010
- Last Updated 08/12/2016
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1881914802
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Silver Spring
Dr. Phuong Trinh
Infectious Disease — Payments: $220,875
Dr. Lynette Posorske, Md, MD
Infectious Disease — Payments: $79,479
Barbara Matthews, Md, Mph, MD, MPH
Infectious Disease — Payments: $36,685
Mrs. Rebecca Shaffer, Md, MD
Infectious Disease — Payments: $9,143
Vasilios Pyrgos, Md, MD
Infectious Disease — Payments: $7,622
Dr. John Mcneil, M.d, M.D
Infectious Disease — Payments: $1,655